Donor-Specific Blood Transfusion in Lung Transplantation.

IF 2.7 3区 医学 Q1 SURGERY
Transplant International Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI:10.3389/ti.2024.12822
Xin Jin, Jacques Pirenne, Robin Vos, Charlotte Hooft, Janne Kaes, Jan Van Slambrouck, Phéline Kortleven, Christelle Vandervelde, Hanne Beeckmans, Pieterjan Kerckhof, Marianne S Carlon, Dirk Van Raemdonck, Mark R Looney, Bart M Vanaudenaerde, Laurens J Ceulemans
{"title":"Donor-Specific Blood Transfusion in Lung Transplantation.","authors":"Xin Jin, Jacques Pirenne, Robin Vos, Charlotte Hooft, Janne Kaes, Jan Van Slambrouck, Phéline Kortleven, Christelle Vandervelde, Hanne Beeckmans, Pieterjan Kerckhof, Marianne S Carlon, Dirk Van Raemdonck, Mark R Looney, Bart M Vanaudenaerde, Laurens J Ceulemans","doi":"10.3389/ti.2024.12822","DOIUrl":null,"url":null,"abstract":"<p><p>Lung transplantation is still hindered by a high rate of chronic rejection necessitating profound immunosuppression with its associated complications. Donor-specific blood transfusion is a pre-transplant strategy aimed at improving graft acceptance. In contrast with standard stored blood or donor-specific regulatory T cells transfusions, this approach utilizes fresh whole blood from the donor prior to allograft transplantation, encompassing all cell types and plasma. The precise mechanisms underlying donor-specific blood transfusion-induced tolerance remain incompletely understood. Associations with regulatory/helper T cells, modulation of mononuclear phagocytic cells or microchimerism have been suggested. While numerous (pre-)clinical studies have explored its application in solid organ transplants like liver, kidney, and intestine, limited attention has been given to the setting of lung transplantation. This comprehensive review summarizes existing knowledge on the mechanisms and outcomes of donor-specific blood transfusion in solid organ transplants both in preclinical and clinical settings. We also address the potential benefits and risks associated with donor-specific blood transfusion in the field of lung transplantation, offering insights into future research directions.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12822"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2024.12822","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Lung transplantation is still hindered by a high rate of chronic rejection necessitating profound immunosuppression with its associated complications. Donor-specific blood transfusion is a pre-transplant strategy aimed at improving graft acceptance. In contrast with standard stored blood or donor-specific regulatory T cells transfusions, this approach utilizes fresh whole blood from the donor prior to allograft transplantation, encompassing all cell types and plasma. The precise mechanisms underlying donor-specific blood transfusion-induced tolerance remain incompletely understood. Associations with regulatory/helper T cells, modulation of mononuclear phagocytic cells or microchimerism have been suggested. While numerous (pre-)clinical studies have explored its application in solid organ transplants like liver, kidney, and intestine, limited attention has been given to the setting of lung transplantation. This comprehensive review summarizes existing knowledge on the mechanisms and outcomes of donor-specific blood transfusion in solid organ transplants both in preclinical and clinical settings. We also address the potential benefits and risks associated with donor-specific blood transfusion in the field of lung transplantation, offering insights into future research directions.

肺移植中的捐献者特异性输血。
由于慢性排斥反应的发生率较高,肺移植手术仍然受到很大的阻碍,因此必须进行深度免疫抑制及其相关并发症。捐献者特异性输血是一种旨在提高移植接受度的移植前策略。与标准的储存血或捐献者特异性调节 T 细胞输血不同,这种方法是在异体移植前使用捐献者的新鲜全血,包括所有细胞类型和血浆。捐献者特异性输血诱导耐受的确切机制仍不完全清楚。有人认为这与调节性/辅助性 T 细胞、单核吞噬细胞或微嵌合体的调节有关。虽然许多(预)临床研究都探讨了其在肝脏、肾脏和肠道等实体器官移植中的应用,但对肺移植的关注却很有限。本综述总结了临床前和临床环境中有关供体特异性输血在实体器官移植中的机制和结果的现有知识。我们还探讨了肺移植领域中与供体特异性输血相关的潜在益处和风险,并对未来的研究方向提出了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplant International
Transplant International 医学-外科
CiteScore
4.70
自引率
6.50%
发文量
211
审稿时长
3-8 weeks
期刊介绍: The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信